🇺🇸 FDA
Pipeline program

Docetaxel

OSU-14152

Phase 2 small_molecule terminated

Quick answer

Docetaxel for Recurrent Squamous Cell Lung Carcinoma is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Karyopharm Therapeutics
Indication
Recurrent Squamous Cell Lung Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials